Showing results (111-120 of 193) with videos related to

Sort By:
Pageof 20
European Journal of Nuclear Medicine and Molecular Imaging|August 26, 2003
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsDamian Wild, Jörg S Schmitt, Mihaela Ginj, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2010
Nephrotoxicity in mice after repeated imaging using 111In-labeled peptidesMarleen Melis, Erik Vegt, Mark W Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 6, 2006
Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in ratsEdgar J Rolleman, Eric P Krenning, Bert F Bernard, et al.
Contrast Media & Molecular Imaging|January 6, 2022
In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid TumorsMarcus C M Stroet, Erik de Blois, Joost Haeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotideMarion de Jong, Raffaella Barone, Eric Krenning, et al.
Clinical and Translational Imaging|April 26, 2014
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developmentsSander M Bison, Mark W Konijnenberg, Marleen Melis, et al.
EJNMMI Research|January 22, 2016
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateHo Sze Chan, Mark W Konijnenberg, Erik de Blois, et al.
Frontiers in Medicine|March 28, 2019
Perspectives on Small Animal Radionuclide Imaging; Considerations and Advances in AtherosclerosisEric J Meester, B J Krenning, J de Swart, et al.
Pageof 20